Plasma efavirenz concentrations and the association with CYP2B6-516G>T polymorphism in HIV-infected Thai Children

Antiviral Therapy

Volumn 14, Issue 3, 2009, Pages 315-320

  Puthanakit, Thanyawee ^a   Tanpaiboom, Pranoot ^b   Aurpibul, Linda ^a   Cressey, Tim R ^a,c   Sirisanthana, Virat ^b  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 2B6; EFAVIRENZ; GLYCINE; LAMIVUDINE; STAVUDINE; TENOFOVIR DISOPROXIL; THREONINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; BODY WEIGHT; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; DELUSION; DEPRESSION; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THAILAND; TOXIC HEPATITIS; TREATMENT OUTCOME; UNPLEASANT DREAM;

ADOLESCENT; ANTI-INFECTIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; THAILAND;

EID: 67649177436     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. World Health Organization. Antiretroviral therapy for HIV infection infants and children in resource-limited settings: towards universal access. Geneva: World Health Organization 2006.
2. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 23 February 2009. US Department of Health and Human Services. (Accessed 10 April 2009.) Available from http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf
3. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
4. McKinney RE Jr, Rodman J, Hu C, et al. Long-term safety and efficacy of a once-daily rgimen of emtricitabine, didanosine nd efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics 2007; 120:e416-e423.
5. Ren Y, Nuttall JJ, Egbers C, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr 2007; 45:133-136.
6. von Hentig N, Koenigs C, Elanjikal S, et al. Need for therapeutic drug monitoring in HTV-1 infected children receiving efavirenz doses according to international guidelines. Eur J Med Res 2006; 11:377-380.
7. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40:1358-1361.
8. Guan S, Huang M, Chan E, Chen X, Duan W, Zhou SF. Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. Eur J Pharm Sci 2006; 29:14-21.
9. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15:861-873.
10. Saitoh A, Fletcher CV, Brundage R, et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr 2007; 45:280-285.
11. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11:399-415.
12. Yamano S, Nhamburo PT, Aoyama T, et al. cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 1989; 28:7340-7348.
13. The National Center for Biotechnology Information. BLASTN. (Accessed 10 April 2009.) Available from http://blast.ncbi.nlm.nih.gov/Blast.cgi
14. Holland DT, DiFrancesco R, Connor JD, Morse GD. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit 2006; 28:367-374.
15. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-2400.
16. Wintergerst U, Hoffmann F, Jansson A, et al. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother 2008; 61:1336-1339.
17. Hoody DW, Fletcher CV. Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children. Semin Pediatr Infect Dis 2003; 14:286-294.
18. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis 2005; 41:100-107.
19. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 44:599-604.
20. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/ or nelfinavir: an Adult AIDS Clinical Trials Group study. J Infect Dis 2005; 192:1931-1942.
21. ter Heine R, Scherpbier HJ, Crommentuyn KM, et al. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir Ther 2008; 13:779-787.
22. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004; 319:1322-1326.
23. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45:1230-1237.
24. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61:914-918.
25. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006; 16:191-198.
26. Saitoh A, Singh KK, Powell CA, et al. An MDR1-343S variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005; 19:371-380.
27. Teglas J-P, Quartier P, Treluyer J-M, Burgard M, Gregoire V, Blanche S. Tolerance of efavirenz in children. AIDS 2001; 15:241-243.
28. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005; 41:1648-1653.
29. Lowenhaupt EA, Matson K, Qureishi B, Saitoh A, Pugatch D. Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. Clin Infect Dis 2007; 45:e128-e130.